The two companies announced an exclusive collaboration agreement that aims to develop treatments that target alpha-synuclein, a protein whose accumulation in the brain causes several neurodegenerative disorders, such as Parkinson’s disease and dementia with Lewy bodies.
Rick Morello spoke with Kevin Price, host of the Price of Business Radio Show, about how the Syn-One Test™ is advancing the way that neurodegenerative diseases like Parkinson’s disease and dementia with Lewy bodies are diagnosed.
News of CND Life Sciences’ $2.4 million grant from the National Institutes of Health is generating interest in news outlets for both healthcare professionals and patients.
Hiring slowed in the healthcare sector across the Valley during the coronavirus pandemic, but that trend is starting to reverse course, fueled in part by growing businesses such as CND Life Sciences.
A group of international experts responded to the publication of the recent Systemic Synuclein Sampling Study (S4), which found alpha-synuclein to be a specific—but not sensitive—marker of Parkinson’s disease. Their letter details how the study’s methods, rather than the specificity of alpha-synuclein as a marker for Parkinson’s disease, may have produced the results.
Drs. Christopher Gibbons and Roy Freeman–two of the founders of CND Life Sciences who also serve as senior medical advisors–recently had their research on orthostatic hypotension as an early sign of Parkinson’s disease and dementia highlighted in a New York Times article.